

Supplemental Material: Tables and Figures

Krett JD, Jewett GA, Elton-Lacasse C, Fonseca F, Hahn C, Au S, Koch MW. Hemorrhagic Encephalopathy Associated with COVID-19.

Table S1

Standard cerebrospinal fluid (CSF) results from day 1 and day 14.

Value	Units	Day 1	Interpretation	Day 14	Interpretation
WBC	x10 ⁶ /L	2	Normal	3	Normal
RBC	x10 ⁶ /L	0	Normal	668	High
Xanthochromia	--	Absent	Normal	Present	Consistent with hemorrhages
Protein	g/l	0.94	High	0.67	High
Glucose	mmol/l	6.1	Serum value: 8.3	5.4	Serum value: 11.1
Opening Pressure	cmH ₂ O	19	Normal	16	Normal
HSV/VZV DNA	PCR	Negative	--	Negative	--
Enterovirus RNA	PCR	Negative	--	Negative	--
Bacterial Culture	--	Negative	--	Negative	--
COVID-19 RNA	PCR	--	--	Negative	--
Oligoclonal Bands	--	--	--	Present	Matched with bands present in serum
AMPAR Ab	--	--	--	Negative	Identical to serum results
NMDA Ab	--	--	--	Negative	Identical to serum results
VGKC Ab	--	--	--	Negative	Identical to serum results
DPPX Ab	--	--	--	Negative	Identical to serum results
GABABR Ab	--	--	--	Negative	Identical to serum results

Krett JD, Jewett GA, Elton-Lacasse C, Fonseca F, Hahn C, Au S, Koch MW. Hemorrhagic Encephalopathy Associated with COVID-19.

HSV = herpes simplex virus; VZV = varicella zoster virus; AMPAR = α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; NMDA-R = *N*-Methyl-d-aspartate receptor; VGKC = voltage-gated potassium channel; DPPX = dipeptidyl-peptidase-like-protein-6; GABABR = gamma aminobutyric acid B receptor; Ab = antibody.

Table S2

	95% Range (pg/ml)			Median (pg/ml)	Inter-quartile range (pg/ml)	St. Dev. (pg/ml)			
sCD30	0	-	27.7	sCD30	2.5	0	-	6.1	37.2
sEGFR	1852	-	7958	sEGFR	3804	2789	-	4743	1806.9
sgp130	15224	-	62771	sgp130	30621	22769	-	37296	16623.8
sIL-1RI	0	-	15.2	sIL-1RI	3.2	1.6	-	5.7	61.9
sIL-1RII	0	-	364	sIL-1RII	21.1	0	-	54.5	151.1
sIL-2Ra	0	-	240	sIL-2Ra	7.2	2.0	-	18.9	182.4
sIL-4R	0	-	35.2	sIL-4R	5.4	2.2	-	9.3	24.0
sIL-6R	396	-	1553	sIL-6R	825	643	-	1016	470.8
sRAGE	0	-	4.1	sRAGE	1.0	0	-	2.5	11.1
sTNFRI	253	-	1309	sTNFRI	495	388	-	704	511.7
sTNFRII	308	-	2760	sTNFRII	665	495	-	1048	1400.4
sVEGFR1	0	-	286.7	sVEGFR1	25.7	0	-	70.3	441.0
sVEGFR2	388	-	2102	sVEGFR2	812	638	-	1086	2375.6
sVEGFR3	0	-	65.1	sVEGFR3	7.9	0	-	17.4	182.6


5% 95% Percentile

25% 75% Percentile

Human Soluble Cytokine Receptor Panel (MILLIPLEX® assay, EMD MilliporeSigma). 95% Range depicts the 5th and 95th percentile based on the normal distribution provided by Eve Technologies, Calgary, Alberta, Canada. Likewise, interquartile range values and standard deviations are depicted. This distribution is derived from 124 patient CSF samples submitted to the laboratory (22 for research use, 102 for experimental clinical diagnostic use).

Figure S1

Cranial CT angiography on day 15. Sagittal (B) and axial (C) images demonstrate no vascular stenoses, occlusions, or alternative sources for the hemorrhages seen on MRI.



Krett JD, Jewett GA, Elton-Lacasse C, Fonseca F, Hahn C, Au S, Koch MW. Hemorrhagic Encephalopathy Associated with COVID-19.

Figure S2

MRI brain on day 21. Axial fluid-attenuated inversion recovery (FLAIR) [A-B] and susceptibility-weighted images (SWI) [C-D] re-demonstrate multifocal hemorrhages with mild surrounding vasogenic edema. Evolution of the hemorrhages, including changes in signal characteristics, are consistent with the expected temporal evolution. Gadolinium enhancement continues to be absent.

